Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Clinical and oncological outcomes of robot-assisted radical prostatectomy with nerve sparing vs. non-nerve sparing for high-risk prostate cancer cases.

Takahara K, Sumitomo M, Fukaya K, Jyoudai T, Nishino M, Hikichi M, Zennami K, Nukaya T, Ichino M, Fukami N, Sasaki H, Kusaka M, Shiroki R.

Oncol Lett. 2019 Oct;18(4):3896-3902. doi: 10.3892/ol.2019.10692. Epub 2019 Jul 31.

2.

Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis.

Watanabe M, Kanao K, Suzuki S, Muramatsu H, Morinaga S, Kajikawa K, Kobayashi I, Nishikawa G, Kato Y, Zennami K, Nakamura K, Tsuzuki T, Yoshikawa K, Ueda R, Sumitomo M.

Prostate. 2019 Oct;79(14):1658-1665. doi: 10.1002/pros.23890. Epub 2019 Aug 7.

PMID:
31390096
3.

Targeting lactate dehydrogenase‑A promotes docetaxel‑induced cytotoxicity predominantly in castration‑resistant prostate cancer cells.

Muramatsu H, Sumitomo M, Morinaga S, Kajikawa K, Kobayashi I, Nishikawa G, Kato Y, Watanabe M, Zennami K, Kanao K, Nakamura K, Suzuki S, Yoshikawa K.

Oncol Rep. 2019 Jul;42(1):224-230. doi: 10.3892/or.2019.7171. Epub 2019 May 24.

PMID:
31180564
4.

PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance.

Zennami K, Choi SM, Liao R, Li Y, Dinalankara W, Marchionni L, Rafiqi FH, Kurozumi A, Hatano K, Lupold SE.

Mol Cancer Res. 2019 Feb;17(2):618-627. doi: 10.1158/1541-7786.MCR-18-0837. Epub 2018 Dec 5.

PMID:
30518628
5.

Impact of a novel biopsy instrument with a 25-mm side-notch needle on the detection of prostate cancer in transrectal biopsy.

Kanao K, Kajikawa K, Kobayashi I, Morinaga S, Muramatsu H, Nishikawa G, Watanabe M, Zennami K, Nakamura K, Sumitomo M.

Int J Urol. 2018 Aug;25(8):746-751. doi: 10.1111/iju.13722. Epub 2018 Jul 18.

6.

Clinical pharmacokinetics and pharmacodynamic target attainment of pazufloxacin in prostate tissue: Dosing considerations for prostatitis.

Nakamura K, Ikawa K, Nishikawa G, Kobayashi I, Narushima M, Muramatsu H, Morinaga S, Kajikawa K, Kato Y, Watanabe M, Zennami K, Kanao K, Morikawa N, Sumitomo M.

J Infect Chemother. 2017 Dec;23(12):809-813. doi: 10.1016/j.jiac.2017.08.005. Epub 2017 Oct 12.

PMID:
28923301
7.

Optimal method for measuring tumor extent in needle biopsy specimens to identify small-volume prostate cancer.

Kajikawa K, Kanao K, Kobayashi I, Nishikawa G, Yoshizawa T, Kato Y, Watanabe M, Zennami K, Nakamura K, Sumitomo M.

Int J Urol. 2016 Jan;23(1):62-8. doi: 10.1111/iju.12961. Epub 2015 Oct 8.

8.

Systemic Administration and Targeted Radiosensitization via Chemically Synthetic Aptamer-siRNA Chimeras in Human Tumor Xenografts.

Ni X, Zhang Y, Zennami K, Castanares M, Mukherjee A, Raval RR, Zhou H, DeWeese TL, Lupold SE.

Mol Cancer Ther. 2015 Dec;14(12):2797-804. doi: 10.1158/1535-7163.MCT-15-0291-T. Epub 2015 Oct 5.

9.

Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics.

Kobayashi I, Ikawa K, Nakamura K, Nishikawa G, Kajikawa K, Yoshizawa T, Watanabe M, Kato Y, Zennami K, Kanao K, Tobiume M, Yamada Y, Mitsui K, Narushima M, Morikawa N, Sumitomo M.

J Infect Chemother. 2015 Aug;21(8):575-80. doi: 10.1016/j.jiac.2015.04.015. Epub 2015 May 14.

PMID:
26050020
10.

Comparative investigation on clinical outcomes of robot-assisted radical prostatectomy between experienced open prostatic surgeons and novice open surgeons in a laparoscopically naïve center with a limited caseload.

Sumitomo M, Kanao K, Kato Y, Yoshizawa T, Watanabe M, Zennami K, Nakamura K.

Int J Urol. 2015 May;22(5):469-74. doi: 10.1111/iju.12711. Epub 2015 Feb 26.

11.

[A case of neuroendocrine carcinoma in a diverticulum of the bladder].

Muramatsu H, Kanao K, Morinaga S, Kajikawa K, Kobayashi I, Nishikawa G, Yoshizawa T, Kato Y, Watanabe M, Zennami K, Nakamura K, Sumitomo M.

Hinyokika Kiyo. 2014 Sep;60(9):439-42. Japanese.

12.

Management of adverse events in patients with metastatic renal cell carcinoma treated with sunitinib and clinical outcomes.

Arakawa-Todo M, Yoshizawa T, Zennami K, Nishikawa G, Kato Y, Kobayashi I, Kajikawa K, Yamada Y, Matsuura K, Tsukiyama I, Saito H, Hasegawa T, Nakamura K, Sumitomo M.

Anticancer Res. 2013 Nov;33(11):5043-50.

PMID:
24222148
13.

Prostatic penetration of meropenem in humans, and dosage considerations for prostatitis based on a site-specific pharmacokinetic/pharmacodynamic evaluation.

Nishikawa G, Ikawa K, Nakamura K, Yamada Y, Zennami K, Mitsui K, Narushima M, Ikeda K, Morikawa N, Sumitomo M.

Int J Antimicrob Agents. 2013 Mar;41(3):267-71. doi: 10.1016/j.ijantimicag.2012.11.001. Epub 2013 Jan 11.

PMID:
23313536
14.

Intravesical administration of pirarubicin against superficial bladder cancer: Relationship between tumor tissue concentration and exposure time in the bladder or therapeutic effect.

Arakawa M, Nakamura K, Yamada Y, Kato K, Katsuda R, Tobiume M, Zennami K, Watanabe M, Kato Y, Nishikawa G, Yoshizawa T, Aoki S, Taki T, Mitsui K, Honda N, Saito H, Hasegawa T.

Exp Ther Med. 2011 Sep;2(5):901-905. Epub 2011 Jun 30.

15.

Retroperitoneal approach for laparoscopic nephroureterectomy with stripping technique: extracorporeal ligation of ureter and ureteral catheter.

Nakamura K, Nagata D, Kajikawa K, Kobayashi I, Zennami K, Nishikawa G, Yoshizawa T, Tobiume M, Aoki S, Yamada Y, Sumitomo M.

Asian J Endosc Surg. 2012 Feb;5(1):42-5. doi: 10.1111/j.1758-5910.2011.00110.x.

PMID:
22776343
16.

Determination of doripenem penetration into human prostate tissue and assessment of dosing regimens for prostatitis based on site-specific pharmacokinetic-pharmacodynamic evaluation.

Nakamura K, Ikawa K, Yamada Y, Arakawa M, Zennami K, Nishikawa G, Ikeda K, Morikawa N, Honda N.

J Chemother. 2012 Feb;24(1):32-7. doi: 10.1179/1120009X12Z.0000000007.

PMID:
22546722
17.

Treatment of upper urinary tract stones with extracorporeal shock wave lithotripsy (ESWL) Sonolith vision.

Nakamura K, Tobiume M, Narushima M, Yoshizawa T, Nishikawa G, Kato Y, Katsuda R, Zennami K, Aoki S, Yamada Y, Honda N, Sumitomo M.

BMC Urol. 2011 Dec 12;11:26. doi: 10.1186/1471-2490-11-26.

18.

Inflammatory pseudotumors of the kidney and the lung presenting as immunoglobulin G4-related disease: a case report.

Nishikawa G, Nakamura K, Yamada Y, Yoshizawa T, Kato Y, Katsuda R, Zennami K, Tobiume M, Aoki S, Taki T, Honda N.

J Med Case Rep. 2011 Sep 25;5:480. doi: 10.1186/1752-1947-5-480.

19.

A new molecular targeted therapeutic approach for renal cell carcinoma with a p16 functional peptide using a novel transporter system.

Zennami K, Yoshikawa K, Kondo E, Nakamura K, Upsilonamada Y, De Velasco MA, Tanaka M, Uemura H, Shimazui T, Akaza H, Saga S, Ueda R, Honda N.

Oncol Rep. 2011 Aug;26(2):327-33. doi: 10.3892/or.2011.1290. Epub 2011 Apr 29.

PMID:
21567093
20.

Lactate dehydrogenase, Gleason score and HER-2 overexpression are significant prognostic factors for M1b prostate cancer.

Yamada Y, Nakamura K, Aoki S, Tobiume M, Zennami K, Kato Y, Nishikawa G, Yoshizawa T, Itoh Y, Nakaoka A, Yoshida E, Uchiyama T, Honda N.

Oncol Rep. 2011 Apr;25(4):937-44. doi: 10.3892/or.2011.1154. Epub 2011 Jan 18.

PMID:
21249322
21.

Significant prognostic factor of immunohistochemical HER-2 expression using initial prostate biopsy specimens with M1b prostate cancer.

Tobiume M, Yamada Y, Nakamura K, Aoki S, Zennami K, Kato Y, Nishikawa G, Yokoi T, Honda N.

Prostate. 2011 Mar 1;71(4):385-93. doi: 10.1002/pros.21252. Epub 2010 Sep 1.

PMID:
20812221
22.

Investigation of risk factors for prostate cancer patients with bone metastasis based on clinical data.

Yamada Y, Naruse K, Nakamura K, Taki T, Tobiume M, Zennami K, Nishikawa G, Itoh Y, Muramatsu Y, Nanaura H, Nishimura M, Takii K, Adham AO, Honda N.

Exp Ther Med. 2010 Jul;1(4):635-639. Epub 2010 Jul 1.

23.

Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder.

Naruse K, Yamada Y, Nakamura K, Aoki S, Taki T, Zennami K, Katsuda R, Watanabe M, Nishikawa G, Itoh Y, Mitsui K, Hibi H, Honda N.

Oncol Rep. 2010 Jun;23(6):1577-83.

PMID:
20428812
24.

Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium.

Yamada Y, Itoh Y, Aoki S, Nakamura K, Taki T, Naruse K, Tobiume M, Zennami K, Katsuda R, Kato Y, Watanabe M, Nishikawa G, Minami M, Nakahira M, Ukai S, Sawada M, Kitamura A, Honda N.

Cancer Chemother Pharmacol. 2009 Nov;64(6):1079-83. doi: 10.1007/s00280-009-0964-2. Epub 2009 Mar 11.

PMID:
19277660
25.

Long-term results and management of ureteral transitional cell carcinoma using the holmium: YAG laser via rigid-ureteroscopy.

Yamada Y, Inoue Y, Nakamura K, Naruse K, Aoki S, Taki T, Tobiume M, Zennami K, Katsuda R, Hara K, Kato Y, Watanabe M, Hayashida K, Suzuki Y, Kato H, Ajisaka R, Kyoku I, Noguchi H, Honda N.

Oncol Rep. 2009 Feb;21(2):345-9.

PMID:
19148506
26.

Cyclooxygenase-2 expression in invasive transitional cell carcinoma of the urinary bladder.

Yamada Y, Nakamura K, Inoue Y, Naruse K, Aoki S, Taki T, Tobiume M, Zennami K, Katsuda R, Hara K, Kyoku I, Mitsutake N, Arakawa M, Saito H, Hasegawa T, Noguchi H, Honda N.

Mol Med Rep. 2008 Nov-Dec;1(6):791-5. doi: 10.3892/mmr_00000030.

PMID:
21479487
27.

Solitary brain metastasis from pT1, G3 bladder cancer.

Zennami K, Yamada Y, Nakamura K, Aoki S, Taki T, Honda N.

Int J Urol. 2008 Jan;15(1):96-8. doi: 10.1111/j.1442-2042.2007.01935.x.

28.

Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.

Matsubara H, Yamada Y, Naruse K, Nakamura K, Aoki S, Taki T, Tobiume M, Zennami K, Katsuda R, Honda N.

Oncol Rep. 2008 Jan;19(1):57-63.

PMID:
18097576
29.

Primary adenocarcinoma of the ureter: report of a case.

Zennami K, Yamada Y, Nakamura K, Katuda R, Tobiume M, Naruse K, Aoki S, Taki T, Honda N.

Hinyokika Kiyo. 2007 Sep;53(9):645-8. Review.

30.

Potential for molecular targeted therapy of HER-2/neu for invasive bladder cancer: examination of gene amplification by fluorescence in situ hybridization.

Yamada Y, Naruse K, Nakamura K, Aoki S, Taki T, Tobiume M, Zennami K, Katsuda R, Hirano M, Hayashida K, Mizumukai E, Nanaura H, Honda N.

Oncol Rep. 2007 Nov;18(5):1183-7.

PMID:
17914570
31.

Lactate dehydrogenase is a prognostic indicator for prostate cancer patients with bone metastasis.

Naruse K, Yamada Y, Aoki S, Taki T, Nakamura K, Tobiume M, Zennami K, Katsuda R, Sai S, Nishio Y, Inoue Y, Noguchi H, Hondai N.

Hinyokika Kiyo. 2007 May;53(5):287-92.

32.

Potential for molecular-targeted therapy targeting human epidermal growth factor receptor-2 for invasive bladder cancer.

Yamada Y, Naruse K, Nakamura K, Aoki S, Taki T, Tobiume M, Zennami K, Katsuda R, Inoue Y, Noguchi H, Honda N.

Oncol Rep. 2007 Jul;18(1):3-7.

PMID:
17549338
33.

An immunohistochemical study of chromogranin A and human epidermal growth factor-2 expression using initial prostate biopsy specimens from patients with bone metastatic prostate cancer.

Yamada Y, Nakamura K, Aoki S, Taki T, Naruse K, Matsubara H, Tobiume M, Zennami K, Katsuda R, Honda N.

BJU Int. 2007 Jan;99(1):189-95. Epub 2006 Oct 11.

34.

Is neuroendocrine cell differentiation detected using chromogranin A from patients with bone metastatic prostate cancer a prognostic factor for outcome?

Yamada Y, Nakamura K, Aoki S, Taki T, Matsubara H, Sai S, Naruse K, Tobiume M, Katsuda R, Zennami K, Honda N, Nakagawa A, Ikeda H.

Oncol Rep. 2006 May;15(5):1309-13.

PMID:
16596203

Supplemental Content

Loading ...
Support Center